Trial · NCT00862745

Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)

NCT00862745, Phase 4, Completed, University of California, San Francisco; results first posted 2011-11-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES). Trials, record NCT00862745. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00862745

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
NCT number: NCT00862745
Status: Completed
Phases: Phase 4
Enrollment: 645 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Fesoterodine, Matching Placebo
First posted: 2009-03-17
Last updated: 2011-11-24
Results first posted: 2011-11-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.	Baseline and Week 12

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.	Baseline and Week 12	The population analyzed included all participants receiving at least 1 dose of study intervention.	episodes	MEAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.	Fesoterodine		-2.5	Standard Deviation 2.5	episodes
Change in Frequency of Urge Urinary Incontinence Episodes at Week 12.	Placebo		-1.8	Standard Deviation 2.7	episodes

Source ClinicalTrials.gov

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Randomized Control Trial	STARTED	Fesoterodine	322
Randomized Control Trial	STARTED	Placebo	323
Randomized Control Trial	COMPLETED	Fesoterodine	284
Randomized Control Trial	COMPLETED	Placebo	284
Randomized Control Trial	NOT COMPLETED	Fesoterodine	38
Randomized Control Trial	NOT COMPLETED	Placebo	39
Open-label Follow-up	STARTED	Fesoterodine	268
Open-label Follow-up	STARTED	Placebo	274
Open-label Follow-up	COMPLETED	Fesoterodine	229
Open-label Follow-up	COMPLETED	Placebo	225

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dry eyes/mouth/throat	Respiratory, thoracic and mediastinal disorders	Fesoterodine	107	322	137
other	Dry eyes/mouth/throat	Respiratory, thoracic and mediastinal disorders	Placebo	38	323	54
other	Constipation	Gastrointestinal disorders	Fesoterodine	24	322	27
other	Constipation	Gastrointestinal disorders	Placebo	17	323	17
other	Headache	Nervous system disorders	Fesoterodine	19	322	22
other	Headache	Nervous system disorders	Placebo	10	323	10
other	Cold/flu	Infections and infestations	Fesoterodine	21	322	21
other	Cold/flu	Infections and infestations	Placebo	15	323	16
other	Urinary tract infection	Renal and urinary disorders	Fesoterodine	17	322	19
other	Urinary tract infection	Renal and urinary disorders	Placebo	14	323	14

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Fesoterodine
Total, all-cause mortality	Placebo
Total, other adverse events	Fesoterodine	148	322
Total, other adverse events	Placebo	88	323
Total, serious adverse events	Fesoterodine	4	322
Total, serious adverse events	Placebo	4	323

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29324595	DERIVED	PubMed
37160401	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Fesoterodine vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00862745

GET https://conductscience.org/api/trials/v1/NCT00862745/events?page=2

API reference For AI assistants